dofequidar has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishikawsa, K; Saeki, T; Sato, W; Tsuruo, T | 1 |
| Aogi, K; Asaga, T; Ikeda, T; Ito, Y; Kobayashi, T; Minami, H; Noguchi, S; Nomizu, T; Ohashi, Y; Saeki, T; Sato, W; Toi, M; Tsuruo, T; Yamamoto, N | 1 |
1 trial(s) available for dofequidar and Breast Neoplasms
| Article | Year |
|---|---|
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Quinolines; Treatment Outcome | 2007 |
1 other study(ies) available for dofequidar and Breast Neoplasms
| Article | Year |
|---|---|
Drug resistance in chemotherapy for breast cancer.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Clinical Trials as Topic; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Mice; Quinolines; Randomized Controlled Trials as Topic | 2005 |